Medicare AdvantageCoverageMedium impact
MA08.188b, Linvoseltamab-gcpt (Lynozyfic)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy for Linvoseltamab-gcpt (Lynozyfic), a specialty pharmaceutical agent, has been posted and will take effect on April 1, 2026. This appears to be a new drug coverage policy that will likely impact billing and prior authorization requirements for this medication.
Action Required
Before April 1, 2026: Billing team should monitor for the full policy details once available to understand coverage criteria, prior authorization requirements, and billing procedures for Linvoseltamab-gcpt (Lynozyfic). Update billing systems and staff training materials accordingly once complete policy guidance is released.